Session date: 
10/30/2019 - 12:00pm to 1:00pm EDT

Michael (Mike) J. Pishvaian, MD, PhD

Associate Professor

The University of Texas M. D. Anderson Cancer Center

Department of Gastrointestinal Medical Oncology

Mike Pishvaian is an Associate Professor, gastrointestinal oncologist, and Co-director for Clinical Research at the Sheikh Ahmed Bin Zayed Al Nahyan Center for Pancreatic Cancer Research at the University of Texas, MD Anderson Cancer Center

Dr. Pishvaian is an MD and a PhD in Tumor Biology, and earned both degrees at Georgetown in 2001.  He remained at Georgetown after graduation, completing his medical residency in 2004, then his fellowship in Hematology/Oncology in 2007.  He served on the faculty at Georgetown until moving to MD Anderson in 2019.

Dr. Pishvaian is a translational oncologist, focused on providing novel therapy for patients, particularly in the areas of pancreatic cancer and refractory colorectal cancer.  His work has been focused in the area of precision medicine, with a special focus on therapy targeted towards homologous recombination DNA repair deficient tumors, and Dr. Pishvaian is a Co-investigator on an NIH RO1 to study mechanisms of resistance to PARP inhibitor-based therapy.

Bluemle Life Sciences Building
233 South 10th Street
Conference Room 101
Philadelphia, PA 19107
United States
Session Summary
Available credit: 
  • 1.00 AMA PRA Category 1 Credit
  • 1.00 Attendance

Please login or register to take this course.